How to improve CDR scale for Alzheimer's research

To paraphrase one of my favourite Alzheimer's researchers, when managing the primary endpoint in an Alzheimer's trial, the focus should be on improving alpha. We help companies improve alpha. 👇 As Drs Kaycee Sink, MD, MAS and Svenja Wacker, PhD point out, administration of the CDR is not without its challenges, due its complexity and subjectivity, and a change in clinicians over the course of a trial can induce significant variability. Cogstate's team of clinicians can deliver centralised (telehealth style) assessment in over 50 languages, increasing reliability, standardisation, and scoring accuracy of CDR data. To learn more, read the blog

Exciting to see our work featured on NBC! The IPAT Study is exploring how controlling blood pressure may help reduce dementia risk by targeting brain changes linked to Alzheimer’s. Read more 👉 https://lnkd.in/gVMhR__c

Research indicates a correlation between elevated homocysteine levels and Alzheimer's disease. Studies reveal that individuals with Alzheimer's often exhibit higher homocysteine levels compared to those without the condition. Vascular dementia, the second most prevalent form of dementia, also demonstrates this association. This connection suggests homocysteine's potential role in vascular damage and reduced cerebral blood flow, key features of vascular dementia. #Alzheimers #VascularDementia #Homocysteine #BrainHealth

Read the blog to learn about a new study that assessed the impact of cardiorespiratory fitness (CRF) on the risk of dementia and AD: https://lnkd.in/gF97UUMY Alzheimer’s disease (AD), the most common form of dementia, is a debilitating and life-altering neurodegenerative condition with significant impacts on those affected and their families, not to mention the economic burden. Gleaning precious insights into how to reduce the risk of this devastating disease, particularly cost-effective interventions, is vital. To this end, a recent study investigated whether exercise could be one such preventative factor.

🧩 Not all decline looks the same. Alzheimer’s, dementia, and other neurocognitive disorders each impact the brain differently — but early functional changes often appear before symptoms do. Firefly helps clinicians distinguish subtle disruptions in brain processing, supporting earlier, more precise diagnosis and care planning. Because identifying the type of decline is the first step toward slowing it. #AlzheimersAwareness #DementiaCare #CognitiveHealth #NeuroTech #FireflyNeuro #ClinicalConfidence

🧩 Not all decline looks the same. Alzheimer’s, dementia, and other neurocognitive disorders each impact the brain differently — but early functional changes often appear before symptoms do. Firefly helps clinicians distinguish subtle disruptions in brain processing, supporting earlier, more precise diagnosis and care planning. Because identifying the type of decline is the first step toward slowing it. #AlzheimersAwareness #DementiaCare #CognitiveHealth #NeuroTech #FireflyNeuro #ClinicalConfidence

Alzheimer’s and dementia research is reshaping our understanding of neurodegeneration. Advancing early detection, biomarkers, and therapy pathways remains critical. Learn more about our biomarker test menu in the new Dementia Testing E-Book, offered through Mayo Clinic BioPharma Diagnostics. #dementia #alzheimers #biotech #biopharma #research

Using a data-driven approach, Siyun Chen and colleagues identified two cognitive subtypes of mild cognitive impairment due to Alzheimer's disease in the ADNI cohort that differed in rates of clinical decline and neurodegeneration. https://lnkd.in/eDFWY-Vi

Proposition 14 passes, bringing $3B to advance dementia research — and the Rice Brain Institute is ready to lead the way. https://bit.ly/497h7u7

The Rice Brain Institute brings together more than 65 of the university’s brightest minds in engineering, neuroscience, cognitive science, ethics and policy.